NCT00741403 - A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Advanced CancerMetastatic CancerLymphomaSolid TumorsAdvanced Malignancies

Interventions

DRUG

CPI-613

CPI-613, the investigational drug, is a novel anti-tumor compound believed to operate via a novel mechanism of action that does not belong to any existing pharmacological class of anticancer agents currently being used in the clinics. Specifically, CPI-613 is Cornerstone Pharmaceutical Inc.'s lead drug from its Altered Energy Metabolism-Directed (AEMD) technology platform. It is selective against tumor cells (but not normal cells)according to preclinical studies

Trial Locations (4)

10469

Eastchester Center for Cancer Care, The Bronx

75201

Mary Crowley Cancer Research Centers, Dallas

85381

Pivotal Research Centers, Peoria

Unknown

British Columbia Cancer Agency, Vancouver